SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-064914
Filing Date
2023-11-17
Accepted
2023-11-17 17:30:08
Documents
12
Period of Report
2023-11-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K virx-20231115.htm   iXBRL 8-K 48264
  Complete submission text file 0000950170-23-064914.txt   162350

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20231115.xsd EX-101.SCH 2454
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20231115_pre.xml EX-101.PRE 9443
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20231115_lab.xml EX-101.LAB 12806
6 EXTRACTED XBRL INSTANCE DOCUMENT virx-20231115_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 231420115
SIC: 2834 Pharmaceutical Preparations